Related Experiment Video
Updated: Aug 24, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
[From gene to diseases; hypokalemic periodic paralysis]
T P Links1, H B Ginjaar, J H van der Hoeven
1Afd. Endocrinologie, Academisch Ziekenhuis, Postbus 30.001, 9700 RB Groningen. t.p.links@int.azg.nl
Abstract:
Hypokalaemic periodic paralysis is an autosomal, dominantly inherited disorder, characterised by attacks of partial or total muscle weakness and serum hypokalaemia. the mutations responsible are located in the CACNA1S gene (type 1) and in the SCN4A gene (type 2), and are all missense mutations where arginine is mostly replaced by histidine or sometimes glycine. The mutation has been localised in the voltage sensor of the transmembrane segment of calcium channel (type 1) and sodium channel (type 2) respectively. How muscle weakness develops is not known. Oral or intravenous administration of potassium is helpful in treating partial or complete attacks. Acetazolamide can reduce the frequency of attacks in type-1 hypokalaemic periodic paralysis.
Related Concept Videos
Poliomyelitis
Generation of Action Potential in Skeletal Muscles
Like neurons, muscle cells are also regarded as excitable due to their capacity to change in response to stimuli, primarily due to voltage-gated ion channels embedded in their plasma membranes, which get activated by alterations in the cell's...
Electrophysiology of Normal Cardiac Rhythm
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antihypertensive Drugs: Potassium-Sparing Diuretics
Pleiotropy

